Using Antiseptic Mouthrinses to Reduce Sars-Cov2 Oral Viral Load
Michele Benegiamo 1, Angelo Sammarro 2 * , Edoardo Rella 1, Antonio D'Addona 3, Franklin Garcia-Godoy 4 5
More Detail
1 Department of Head and Neck, Oral Surgery and Implantology Unit, Institute of Clinical Dentistry, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ITALY
2 Department of Applied Pharmaceutical Sciences – Quality Control, Università Degli Studi di Firenze, Firenze, ITALY
3 Professor and Head, Department of Head and Neck, Oral Surgery and Implantology Unit, Institute of Clinical Dentistry, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, ITALY
4 Professor and Director, Bioscience Research Center, College of Dentistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA
5 Senior Clinical Investigator, The Forsyth Center, Cambridge, Massachusetts, USA
* Corresponding Author

Abstract

Virucidal activity of Povidone-Iodine (PVP-I) have not yet been performed specifically on SARS-CoV-2. There have been in vitro studies demonstrating its effectiveness against multiple viruses including related coronaviruses. PVP-I could be effective to reduce viral load from asymptomatic COVID-19 patients and also provide a protective oropharyngeal hygiene measure for the health professionals.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Short Communication

https://doi.org/10.29333/ejgm/9616

Electron J Gen Med, 2021 - Volume 18 Issue 1, Article No: em273

Publication date: 20 Jan 2021

Article Views: 582

Article Downloads: 681

Open Access References How to cite this article